• Ten-year results of FAST: a randomised controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer 

  Bliss, J; Haviland, JS; Sydenham, M; Yarnold, J
• Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600-Wild-Type Colorectal Cancer. 

  Georgiou, A; Stewart, A; Cunningham, D; Banerji, U; Whittaker, SR (2020-02-25)

  Through the use of an unbiased, genome-scale CRISPR modifier screen, we identified NF1 suppression as a mechanism of resistance to EGFR inhibition in NRAS/KRAS/BRAFV600 -wild-type colorectal cancer cells. Reduced NF1 ...
• A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. 

  Kolinsky, MP; Rescigno, P; Bianchini, D; Zafeiriou, Z; Mehra, N; Mateo, J; Michalarea, V; Riisnaes, R; Crespo, M; Figueiredo, I; Miranda, S; Nava Rodrigues, D; Flohr, P; Tunariu, N; Banerji, U; Ruddle, R; Sharp, A; Welti, J; Lambros, M; Carreira, S; Raynaud, FI; Swales, KE; Plymate, S; Luo, J; Tovey, H; Porta, N; Slade, R; Leonard, L; Hall, E; de Bono, JS (2020-02-21)

  BACKGROUND:Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration-resistant prostate cancer (mCRPC). Recent evidence ...
• Combination therapy with oncolytic viruses and immune checkpoint inhibitors. 

  Chiu, M; Armstrong, EJL; Jennings, V; Foo, S; Crespo-Rodriguez, E; Bozhanova, G; Patin, EC; McLaughlin, M; Mansfield, D; Baker, G; Grove, L; Pedersen, M; Kyula, J; Roulstone, V; Wilkins, A; McDonald, F; Harrington, K; Melcher, A (2020-02-23)

  Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relatively low, in part due to ...
• Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. 

  Lau, D; Kalaitzaki, E; Church, DN; Pandha, H; Tomlinson, I; Annels, N; Gerlinger, M; Sclafani, F; Smith, G; Begum, R; Crux, R; Gillbanks, A; Wordsworth, S; Chau, I; Starling, N; Cunningham, D; Dhillon, T (2020-02)

  BACKGROUND:10%-15% of early-stage colon cancers harbour either deficient mismatch repair (dMMR), microsatellite instability high (MSI-H) or POLE exonuclease domain mutations, and are characterised by high tumour mutational ...
• Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. 

  James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; Parker, CC; Ritchie, AWS; Russell, JM; Schiavone, F; Attard, G; de Bono, JS; Birtle, A; Engeler, DS; Elliott, T; Matheson, D; O'Sullivan, J; Pudney, D; Srihari, N; Wallace, J; Barber, J; Syndikus, I; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2016-03)

  IMPORTANCE:The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. ...
• Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

  James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR; Ritchie, AWS; Parker, CC; Russell, JM; Attard, G; de Bono, J; Cross, W; Jones, RJ; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, DB; O'Sullivan, JM; Parikh, O; Peedell, C; Protheroe, A; Robinson, AJ; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, MKB; STAMPEDE investigators (2016-03)

  BACKGROUND:Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with ...
• Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. 

  Li, Y; Yang, R; Henzler, CM; Ho, Y; Passow, C; Auch, B; Carreira, S; Nava Rodrigues, D; Bertan, C; Hwang, TH; Quigley, DA; Dang, HX; Morrissey, C; Fraser, M; Plymate, SR; Maher, CA; Feng, FY; de Bono, JS; Dehm, SM (2020-01-13)

  PURPOSE:Prostate cancer is the second leading cause of male cancer deaths. Castration-resistant prostate cancer (CRPC) is a lethal stage of the disease that emerges when endocrine therapies are no longer effective at ...
• Circulating cell-free DNA: Translating prostate cancer genomics into clinical care. 

  Gasi Tandefelt, D; de Bono, J (2020-01-16)

  Only in the past decade tremendous advances have been made in understanding prostate cancer genomics and consequently in applying new treatment strategies. As options regarding treatments are increasing so are the challenges ...
• CALIBER - A phase II randomised feasibility trial of chemoablation with mitomycin versus surgical management in low risk non-muscle invasive bladder cancer. 

  Mostafid, AH; Porta, N; Cresswell, J; Griffiths, T; Kelly, JD; Penegar, SR; Davenport, K; McGrath, JS; Campain, N; Cooke, P; Masood, S; Knowles, MA; Feber, A; Knight, A; Catto, JW; Lewis, R; Hall, E (2020-03-03)

  OBJECTIVES:To evaluate the activity of intravesical mitomycin C (MMC) to ablate recurrent low risk non-muscle invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for ...
• The kinase polypharmacology landscape of clinical PARP inhibitors. 

  Antolin, AA; Ameratunga, M; Banerji, U; Clarke, PA; Workman, P; Al-Lazikani, B (2020-02-17)

  Polypharmacology plays an important role in defining response and adverse effects of drugs. For some mechanisms, experimentally mapping polypharmacology is commonplace, although this is typically done within the same protein ...
• Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. 

  Pettitt, AR; Jackson, R; Cicconi, S; Polydoros, F; Yap, C; Dodd, J; Bickerstaff, M; Stackpoole, M; Khan, UT; Carruthers, S; Oates, M; Lin, K; Coupland, SE; Menon, G; Kalakonda, N; McCarthy, H; Bloor, A; Schuh, A; Duncombe, A; Dearden, C; Fegan, C; Kennedy, B; Walewska, R; Marshall, S; Fox, CP; Hillmen, P (2020-02-13)
• Applications of liquid biopsies in metastatic castration resistant prostate cancer 

  Sumanasuriya, S (2020-02-29)

  Despite many recent advances, treating advanced prostate cancer (PC) remains clinically challenging. The need for vaildated circulating biomarkers is well recognised in almost all cancers, including in PC. Whilst circulating ...
• Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. 

  Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Bossi, A; Briganti, A; Bristow, RG; Chi, KN; Clarke, N; Davis, ID; de Bono, J; Drake, CG; Duran, I; Eeles, R; Efstathiou, E; Evans, CP; Fanti, S; Feng, FY; Fizazi, K; Frydenberg, M; Gleave, M; Halabi, S; Heidenreich, A; Heinrich, D; Higano, CTS; Hofman, MS; Hussain, M; James, N; Kanesvaran, R; Kantoff, P; Khauli, RB; Leibowitz, R; Logothetis, C; Maluf, F; Millman, R; Morgans, AK; Morris, MJ; Mottet, N; Mrabti, H; Murphy, DG; Murthy, V; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Parker, C; Poon, DMC; Pritchard, CC; Reiter, RE; Roach, M; Rubin, M; Ryan, CJ; Saad, F; Sade, JP; Sartor, O; Scher, HI; Shore, N; Small, E; Smith, M; Soule, H; Sternberg, CN; Steuber, T; Suzuki, H; Sweeney, C; Sydes, MR; Taplin, M-E; Tombal, B; Türkeri, L; van Oort, I; Zapatero, A; Omlin, A (2020-04)

  BACKGROUND:Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform ...
• From patent to patient: analysing access to innovative cancer drugs. 

  Sharpe, E; Hoey, R; Yap, C; Workman, P (2020-01-29)

  Analysis of cancer drugs licensed through the European Medicines Agency (EMA) in 2000-2016 shows that the number of authorisations increased over that timeframe. The median number of licensed drugs each year rose from six ...
• Genomics of lethal prostate cancer at diagnosis and castration resistance. 

  Mateo, J; Seed, G; Bertan, C; Rescigno, P; Dolling, D; Figueiredo, I; Miranda, S; Nava Rodrigues, D; Gurel, B; Clarke, M; Atkin, M; Chandler, R; Messina, C; Sumanasuriya, S; Bianchini, D; Barrero, M; Petermolo, A; Zafeirou, Z; Fontes, M; Perez-Lopez, R; Tunariu, N; Fulton, B; Jones, R; McGovern, U; Ralph, C; Varughese, M; Parikh, O; Jain, S; Elliott, T; Sandhu, S; Porta, N; Hall, E; Yuan, W; Carreira, S; de Bono, JS (2020-02-24)

  The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, ...
• Optimising trial methodologies to maximise trial efficiencies: a case study in breast cancer radiotherapy trials 

  Bhattacharya, I (2020-01-31)

  Background: In an era of falling local relapse rates, the risk-benefit ratio of adjuvant breast radiotherapy requires careful consideration, and the collection of normal tissue effect (NTE) data optimised. For patients at ...
• Derivation of dose/volume constraints for the anorectum from clinician and patient-reported outcomes in the CHHiP trial of radiotherapy fractionation. 

  Wilkins, A; Naismith, O; Brand, D; Fernandez, K; Hall, E; Dearnaley, D; Gulliford, S; CHHiP Trial Management Group (2020-01-24)

  BACKGROUND:The CHHiP trial randomised 3216 men with localised prostate cancer (1:1:1) to three radiotherapy fractionation schedules: 74Gy/37 fractions (f) over 7.4 weeks, 60Gy/20f/4 weeks and 57Gy/19f/3.8 weeks. Literature-based ...
• Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial. 

  Murray, J; Gulliford, S; Griffin, C; Wilkins, A; Syndikus, I; Staffurth, J; Panades, M; Scrase, C; Parker, C; Khoo, V; Dean, J; Mayles, H; Mayles, P; Thomas, S; Naismith, O; Mossop, H; Cruickshank, C; Hall, E; Dearnaley, D; CHHiP Investigators (2020-03)

  Background and purpose:The penile bulb (PB) dose may be critical in development of post prostate radiotherapy erectile dysfunction (ED). This study aimed to generate PB dose constraints based on dose-volume histograms ...
• Phospho-proteomics and functional genomics for the characterisation of resistance mechanisms to agents targeting the EGFR, PI3K and MAPK pathways and their application in guiding drug combinations in colorectal cancer 

  Georgiou, A (2019-12-31)

  KRAS mutant and RAS/BRAF wild type (RAS WT) colorectal cancer (CRC) cells respond differently to targeted agents, as exemplified by cetuximab, an anti-EGFR antibody, which is only effective in a proportion of patients with ...

View more